In an article, Dr. Hiroki Yukami discusses findings from the GALAXY trial presented during the 2024 ASCO Gastrointestinal Cancers Symposium.

“These results show that ctDNA is a promising prognostic and predictive marker for recurrence.”—Dr. Hiroki Yukami